[January 24, 2017]

SHAREHOLDER ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit against Mallinckrodt PLC and Encourages Investors with Losses to Contact the Firm

Goldberg Law PC, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Mallinckrodt PLC ("Mallinckrodt" or the "Company") (NYSE: MNK). Investors who purchased or otherwise acquired Mallinckrodt shares between November 25, 2014 and January 18, 2017 inclusive (the "Class Period"), are encouraged to contact the firm in advance of the March 27, 2017 lead plaintiff deadline.

If you are a shareholder who suffered a loss during the Class Period, we encourage you to click here, or contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars, Suite 1100, Los Angeles CA (News - Alert) 90067, at 800-977-7401, to discuss your rights free of charge. You can also reach us through the firm's website at http://www.Goldberglawpc.com, or by email at [email protected].

The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, during the Class Period, Mallinckrodt and its Chief Executive Officer, Mark Trudeau, issued a series of false and misleading statements and failed to disclose material adverse facts about the eventual sustainability of the Company's monopolistic HP Acthar Gel ("Acthar") profits and the exposure of Acthar to reimbursement rates by Medicare and Medicaid. In particular, Defendants issued false and/or misleading statements and/or failed to disclose that Acthar's monopoly status as the sole FDA-approved adrenocorticotropic hormone preparation was the result of unlawful anticompetitive practices and failed to reveal that its growing reliance on Medicare and Medicaid meant that Mallinckrodt's monopolistic Acthar revenue would be jeopardized if the government took action to limit the price paid for this drug by taxpayers.

When this information was released to the public, the value of Mallinckrodt fell sharply, causing investors harm.

Goldberg Law PC represents shareholders around the world and specializes in securities class actions and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170124006633/en/

[ Back To TMCnet.com's Homepage ]